Pharmaceutical Executive Daily: Novo Nordisk's Amended Acquisition Proposal

Nov 06, 08:05 PM

Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are transforming pharma’s next frontier in commercial customer engagement.

Share
Subscribe
Next
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1's to TrumpRX
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
by Pharmaceutical Executive